1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Hyperglycemia - Pipeline Review, H2 2016

Hyperglycemia - Pipeline Review, H2 2016

  • December 2016
  • -
  • Global Markets Direct
  • -
  • 44 pages

Hyperglycemia - Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Hyperglycemia – Pipeline Review, H2 2016, provides an overview of the Hyperglycemia (Metabolic Disorders) pipeline landscape.

Hyperglycemia is a condition that occurs when blood glucose levels get too high. Several factors can contribute to hyperglycemia, including food and physical activity choices, illness, non-diabetes medications, or not taking enough glucose-lowering medication. Symptoms include frequent urination, blurred vision, fatigue headache, nausea and vomiting, dry mouth, coma and confusion. Treatment includes anti-hyperglycemic therapy and insulin therapy.


Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Hyperglycemia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hyperglycemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperglycemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperglycemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 1 molecules, respectively.Hyperglycemia.

Hyperglycemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperglycemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Hyperglycemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hyperglycemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hyperglycemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hyperglycemia (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hyperglycemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hyperglycemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Hyperglycemia - Pipeline Review, H2 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hyperglycemia Overview 6
Therapeutics Development 7
Pipeline Products for Hyperglycemia - Overview 7
Pipeline Products for Hyperglycemia - Comparative Analysis 8
Hyperglycemia - Therapeutics under Development by Companies 9
Hyperglycemia - Therapeutics under Investigation by Universities/Institutes 10
Hyperglycemia - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Hyperglycemia - Products under Development by Companies 13
Hyperglycemia - Products under Investigation by Universities/Institutes 14
Hyperglycemia - Companies Involved in Therapeutics Development 15
Eli Lilly and Company 15
Kissei Pharmaceutical Co Ltd 16
Mitsubishi Tanabe Pharma Corp 17
PhaseBio Pharmaceuticals Inc 18
Hyperglycemia - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
CDR-267F018 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
RandD Progress 28
Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile 29
Product Description 29
Mechanism Of Action 29
RandD Progress 29
FGH-10019 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
RandD Progress 30
KR-62980 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
RandD Progress 31
PE-0139 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
RandD Progress 33
Recombinant Peptide to Agonize Glucagon Receptor for Hyperglycemia - Drug Profile 35
Product Description 35
Mechanism Of Action 35
RandD Progress 35
Small Molecule to Inhibit SGLT1 for Postprandial Hyperglycemia - Drug Profile 36
Product Description 36
Mechanism Of Action 36
RandD Progress 36
Small Molecules to Antagonize PST Receptor for Dysglycemic States - Drug Profile 37
Product Description 37
Mechanism Of Action 37
RandD Progress 37
Small Molecules to Inhibit DPP-IV for Hyperglycemia - Drug Profile 38
Product Description 38
Mechanism Of Action 38
RandD Progress 38
Small Molecules to Inhibit PEPCK for Type 2 Diabetes and Hyperglycemia - Drug Profile 39
Product Description 39
Mechanism Of Action 39
RandD Progress 39
Small Molecules to Inhibit Prokineticin Receptor for Metabolic Disorders - Drug Profile 40
Product Description 40
Mechanism Of Action 40
RandD Progress 40
Synthetic Peptides to Antagonize Glucagon Receptor for Hyperglycemia and Type 2 Diabetes - Drug Profile 41
Product Description 41
Mechanism Of Action 41
RandD Progress 41
Hyperglycemia - Dormant Projects 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 43
Disclaimer 44

List of Tables
Number of Products under Development for Hyperglycemia, H2 2016 7
Number of Products under Development for Hyperglycemia - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Hyperglycemia - Pipeline by Eli Lilly and Company, H2 2016 15
Hyperglycemia - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2016 16
Hyperglycemia - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2016 17
Hyperglycemia - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2016 18
Assessment by Monotherapy Products, H2 2016 19
Number of Products by Stage and Target, H2 2016 21
Number of Products by Stage and Mechanism of Action, H2 2016 23
Number of Products by Stage and Route of Administration, H2 2016 25
Number of Products by Stage and Molecule Type, H2 2016 27
Hyperglycemia - Dormant Projects, H2 2016 42

List of Figures
Number of Products under Development for Hyperglycemia, H2 2016 7
Number of Products under Development for Hyperglycemia - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy Products, H2 2016 19
Number of Products by Targets, H2 2016 20
Number of Products by Stage and Targets, H2 2016 20
Number of Products by Mechanism of Actions, H2 2016 22
Number of Products by Stage and Mechanism of Actions, H2 2016 22
Number of Products by Routes of Administration, H2 2016 24
Number of Products by Stage and Routes of Administration, H2 2016 24
Number of Products by Molecule Types, H2 2016 26
Number of Products by Stage and Molecule Types, H2 2016 26

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016’, provides in depth analysis ...

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) ...

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016 ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.